The latest in peptides — new research, FDA moves, safety signals, and what's changing for the people who use them. Every story links back to where it came from.
The GLP-1 receptor agonist efficacy ladder keeps climbing: semaglutide (~15% mean weight loss), the dual GIP/GLP-1 agonist tirzepatide (~21%), and triple agonists such as retatrutide (glucagon/GIP/GLP-1) reporting even greater reductions in Phase 2. The 2026 pipeline is crowded with next-generation candidates aiming for greater efficacy, oral delivery, and muscle preservation.
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee recommended adding six of seven reviewed peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) to the Section 503A Bulks List and rejected Emideltide/DSIP. The vote is advisory only — not a final FDA decision and not legal authorization to compound. FDA must still complete formal notice-and-comment rulemaking (typically 12–24 months) before any change in legal status.
Researchers report that an experimental peptide-based drug reversed myelin damage in a mouse model of multiple sclerosis, suggesting a possible repair-focused therapy. The findings come from preclinical work, and human trials have not yet begun. The approach is moving toward clinical translation.
Novo Nordisk announced topline results showing CagriSema, a fixed-dose combination of cagrilintide and semaglutide, produced greater weight loss than tirzepatide in adults with type 2 diabetes in the REIMAGINE 5 trial (12.4% vs. 9.1% at 60 weeks), while achieving noninferior HbA1c reductions. In the REDEFINE 9 trial, CagriSema led to 21% weight loss at 68 weeks in adults with overweight or obesity without diabetes. These are topline company-announced results from ongoing trial programs.
TheDoseReport published a consumer-oriented guide comparing the GLP-1 medications semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) for weight management. The piece explains how GLP-1 receptor agonists work, citing average weight loss of about 13.7% for semaglutide and 20.2% for tirzepatide in clinical trials. It also discusses dosing, cost differences, and the idea that the best choice depends on individual health factors.
Semaglutide's patent expires in India on March 24, 2026, and generic versions could cut prices by about 90%. However, access may be limited by eligibility rules based on a BMI threshold of 27, derived from the SELECT trial's predominantly white cohort. The authors argue this threshold ignores the 'thin-fat phenotype' common in South Asian populations, who face elevated cardiovascular risk at lower BMIs. They call for India-specific evidence and guidelines to determine who should qualify for generic semaglutide.
A November 2025 New York Times explainer takes a skeptical consumer lens to the peptide-therapy craze, separating the few uses with reasonable evidence (topical GHK-Cu and Matrixyl-type peptides in skincare) from the largely unproven injectable and "biohacking" market (BPC-157, TB-500, epitalon, semax, selank). Dermatologists frame cosmetic peptides as "sidekicks, not hero ingredients," while endocrinologists warn that growth-hormone-releasing peptides like sermorelin and tesamorelin carry the same long-term risks as HGH — diabetes, certain cancers, and acromegaly. The piece notes that most longevity claims rest on cell-culture or animal data only, and that "research-grade" products have no quality controls.
A November 2025 CNN report documents how celebrities and wellness influencers are fueling mass consumer use of unapproved peptides like BPC-157, TB-500, ipamorelin, and CJC-1295, many sold with a "for research use only" label that lawyers and regulators describe as a loophole to evade FDA oversight. Health Secretary Robert F. Kennedy Jr. has vowed to end the agency's "war on peptides," while named sellers such as biohacker Gary Brecka market injectable vials for $350 to $600 each. Independent experts — including Scripps' Dr. Eric Topol and UC Davis biologist Paul Knoepfler — stress that none of these compounds have passed adequate clinical trials and that "research-grade" powders often contain contaminants. BPC-157 and TB-500 are also banned by international sports authorities as doping substances.
Telehealth companies like Noom, Found, and Hims & Hers are aggressively marketing 'microdosed' GLP-1 agonists, such as semaglutide and tirzepatide, for weight loss and metabolic health. These programs utilize compounded drugs at doses lower than FDA-approved standards, claiming benefits like reduced inflammation and cognitive risk. However, medical experts emphasize that robust clinical evidence supporting the efficacy or safety of these very low doses is currently lacking.
Dr. Anne Marie Morse discusses the cognitive impacts of obstructive sleep apnea (OSA), including inflammation and risks for dementia and stroke. She notes that women are often underdiagnosed due to subtle symptoms. While expanding treatment options, she specifically identifies tirzepatide as a groundbreaking medication for managing the condition.
An analysis suggests GLP-1 receptor agonist drugs show no strong signal of psychiatric harm, though one unexplained finding warrants continued monitoring. The reassurance matters given wide patient exposure and prior concerns about mood effects. Clinicians are advised to remain vigilant for rare or subgroup-specific neuropsychiatric events.
Law firm Parker Waichman LLP has filed multiple lawsuits alleging patients developed NAION, an irreversible eye condition causing permanent vision loss, after taking Novo Nordisk's semaglutide drugs Ozempic and Wegovy. The lawsuits cite research linking semaglutide to increased NAION risk. The litigation alleges the manufacturer failed to adequately warn about the eye-injury risk.
Law firm Parker Waichman has filed multiple lawsuits alleging that patients developed NAION, a rare and irreversible optic nerve condition causing permanent vision loss, after taking Novo Nordisk's semaglutide drugs Wegovy and Ozempic. A Massachusetts plaintiff's suit was filed on June 5, 2026. The claims cite studies, including one in JAMA Ophthalmology and Mass Eye and Ear research, suggesting increased NAION risk among semaglutide users. The litigation alleges the manufacturer failed to adequately warn about the risk.
Despite FDA resolution of GLP-1 drug shortages, compounded (non-FDA-approved) versions of semaglutide and tirzepatide remain widely sold through clinics and medical spas. Data presented at the Obesity Medicine Association annual meeting show some suppliers have inconsistent licensure or FDA disciplinary action. Researchers highlight ongoing safety and quality concerns with compounded GLP-1s.
A cross-sectional analysis of the FDA FAERS database indicates that while cutaneous adverse events associated with GLP-1 receptor agonists are statistically rare, they do occur. The most frequently reported reactions included rash, pruritus, and injection site reactions. Researchers suggest that switching from daily to weekly formulations may mitigate these skin-related side effects in sensitive patients.
A systematic review and network meta-analysis of 39 studies (33,354 participants) assessed gastrointestinal adverse events of GLP-1 receptor agonists in non-diabetic patients with overweight or obesity. Nausea, vomiting, diarrhea, and constipation were the most common side effects. Orforglipron showed the highest nausea risk, followed by exenatide, tirzepatide, semaglutide, and liraglutide. The differing safety profiles can help clinicians tailor weight-loss therapy choices.
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee recommended adding six of seven reviewed peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) to the Section 503A Bulks List and rejected Emideltide/DSIP. The vote is advisory only — not a final FDA decision and not legal authorization to compound. FDA must still complete formal notice-and-comment rulemaking (typically 12–24 months) before any change in legal status.
The FDA approved rusfertide (Mimrylo, from Protagonist Therapeutics and Takeda) for erythrocytosis in adults with polycythemia vera who haven't achieved adequate control on other treatments. The approval rests on the phase 3 VERIFY trial, where 76.9% of rusfertide patients needed no phlebotomy between weeks 20 and 32 versus 32.9% on placebo. Dosing is weekly subcutaneous injection starting at 19 mg. Rusfertide is a hepcidin mimetic — the connection to the iron-regulatory peptide named in the companion research review; this article itself focuses on clinical results, dosing, and safety warnings.
Medivir has received a Notice of Allowance from the US Patent and Trademark Office for a patent covering the combination of its peptide prodrug fostrox and lenvatinib for treating liver cancers. This approval strengthens the company's intellectual property position in the US market, extending potential market exclusivity for this combination therapy until at least 2041.
A federal advisory panel has narrowly voted to recommend easing FDA restrictions on the compounding of specific peptides, including BPC-157 and TB-500. This advice, which is not binding, contradicts FDA scientists who warn of insufficient safety and efficacy data. The decision aligns with the views of Health Secretary Robert F. Kennedy Jr. and could lead to increased availability of these substances through telehealth and compounding pharmacies.
The European Commission has approved Novo Nordisk's oral semaglutide 25 mg tablet (Wegovy pill) for weight management, marking the first oral GLP-1 receptor agonist available in the EU. The approval is for adults with obesity or overweight with comorbidities. Additionally, the EC approved a 7.2 mg single-dose pen injection. Novo Nordisk plans to launch the tablet in the EU in the second half of 2026.
CLINUVEL's afamelanotide implant, the world's first systemic photoprotective drug, has won approval in Canada for preventing phototoxic reactions in adults with erythropoietic protoporphyria (EPP) — a rare disorder where daylight causes severe pain and burns. Canada becomes the fourth major market for the 16 mg implant after Europe, the USA and Australia, where it has now been given more than 21,000 times.
An analysis of a deal between the Trump administration and Eli Lilly and Novo Nordisk regarding the pricing of GLP-1 agonists. The agreement aimed to lower drug costs to $245 monthly for Medicare and Medicaid in exchange for increased volume, but private insurers' reluctance to cover obesity treatments has complicated the implementation. The article suggests that while the policy intended to expand access, the pharmaceutical giants are likely to benefit from the increased volume without significantly sacrificing price.
A vendor breakdown (Durham Peptides, published 27 June 2026) walks through the KLOW four-peptide blend - GHK-Cu for collagen and gene expression, BPC-157 for vessel growth, TB-500 for cell migration, KPV for inflammation - including ratios and per-component pricing versus buying separately. Vendor content: claims are the seller's own, not independent findings.
The U.S. government is launching a demonstration program to make obesity drugs, such as GLP-1 receptor agonists, available to Medicare beneficiaries for the first time. This initiative, named the Bridge program, circumvents the statutory ban on Medicare coverage for obesity treatments by utilizing a temporary coverage model. The move follows resistance from private insurers regarding a previously proposed voluntary coverage structure.
Medicare drug spending is rising faster than anticipated, largely due to the surging utilization of GLP-1 medications. This trend is occurring alongside the financial impacts of the Democrats' redesign of Part D drug coverage. The increased cost burden highlights the growing influence of peptide-based weight loss drugs on federal healthcare budgets.
Medicare is preparing to offer weight loss coverage for GLP-1 drugs like Wegovy and Zepbound starting in July 2026, with a patient copay of $50. However, the Centers for Medicare and Medicaid Services (CMS) has not released data estimating the total cost to taxpayers for this new benefit. The lack of financial transparency comes despite the fact that taxpayers will fund the majority of the expenses for these high-cost therapies.
On May 21, 2026, Eli Lilly reported that its triple-agonist candidate retatrutide delivered up to 28% mean weight loss among treatment completers on the 12 mg dose in the pivotal TRIUMPH-1 Phase 3 trial, which randomized roughly 2,339 people with obesity and followed them over 80 weeks. The 'triple-G' molecule — targeting GLP-1, GIP, and glucagon receptors — is positioned as a potential best-in-class challenger to semaglutide and tirzepatide. Lower-dose arms achieved about 26% (9 mg) and 19% (4 mg) mean weight loss versus 2% for placebo, and the positive topline readout was flagged as a new high-water mark for the obesity pipeline.
Novo Nordisk announced topline results showing CagriSema, a fixed-dose combination of cagrilintide and semaglutide, produced greater weight loss than tirzepatide in adults with type 2 diabetes in the REIMAGINE 5 trial (12.4% vs. 9.1% at 60 weeks), while achieving noninferior HbA1c reductions. In the REDEFINE 9 trial, CagriSema led to 21% weight loss at 68 weeks in adults with overweight or obesity without diabetes. These are topline company-announced results from ongoing trial programs.
A new analysis of the SELECT trial published in JAMA Cardiology found that semaglutide 2.4 mg (Wegovy) delivered cardiovascular benefits versus placebo consistently across all frailty levels. The most frail patients experienced the greatest quality-of-life improvements. The findings address concerns that GLP-1 therapies may be less safe or effective in frail populations.
A comparative study evaluated tirzepatide and semaglutide for asthma outcomes, finding the difference between the two GLP-1-based drugs was smaller than anticipated. Both peptides showed potential benefits in asthma control, likely linked to weight loss and anti-inflammatory effects. The findings suggest either drug may help patients with obesity-related asthma.
Topline results from the STEP Young trial show once-weekly injectable semaglutide (Wegovy) produced greater BMI reductions than placebo in children aged 6 to 11 with obesity. Of children receiving semaglutide, 40.4% were no longer classified as having obesity after 68 weeks, while all placebo participants still met obesity criteria. Safety and tolerability were consistent with prior semaglutide studies.
New real-world evidence indicates that tirzepatide significantly reduces the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. The study, utilizing U.S. claims databases, compared tirzepatide against sitagliptin and found the GLP-1 agonist offered superior protection for heart health. Additionally, the data suggested a decrease in infection-related hospitalizations for patients taking the medication.
Pharmability has received regulatory approval from the Swedish Medical Products Agency to initiate a Phase Ib clinical trial for its lead candidate, TIR-C, targeting atopic dermatitis. This first-in-human study, to be conducted in Sweden, is designed to evaluate the safety and tolerability of the peptide drug while also exploring early efficacy signals. The transition to clinical testing marks a significant milestone for the company after several years of preclinical development.
The GLP-1 receptor agonist efficacy ladder keeps climbing: semaglutide (~15% mean weight loss), the dual GIP/GLP-1 agonist tirzepatide (~21%), and triple agonists such as retatrutide (glucagon/GIP/GLP-1) reporting even greater reductions in Phase 2. The 2026 pipeline is crowded with next-generation candidates aiming for greater efficacy, oral delivery, and muscle preservation.
Researchers report that an experimental peptide-based drug reversed myelin damage in a mouse model of multiple sclerosis, suggesting a possible repair-focused therapy. The findings come from preclinical work, and human trials have not yet begun. The approach is moving toward clinical translation.
An abstract presented at the 2026 European Respiratory Society International Congress links semaglutide use in patients with type 2 diabetes to fewer exacerbations in asthma (38% reduction) and COPD (21% reduction). Other GLP-1 receptor agonists like exenatide and dulaglutide also showed exacerbation reductions. The associations persisted regardless of weight or glycemic changes, suggesting possible direct lung anti-inflammatory effects.
A Swedish national cohort study of 14,694 people with bipolar disorder found that semaglutide use was associated with a lower risk of psychiatric hospitalization, with no concerning safety signals such as suicidality. Published in Acta Psychiatrica Scandinavica, the study analyzed 2009-2024 registry data from patients using diabetes medications. This is the first study to evaluate GLP-1 receptor agonists in people with bipolar disorder, despite frequent co-occurrence of diabetes, obesity, and bipolar disorder.
A study reported that semaglutide extended lifespan in older female mice, with additional findings beyond longevity. The results add to growing preclinical interest in GLP-1 receptor agonists and aging. However, the data come from animal research and may not translate directly to humans.
A new analysis of 6,239 adults found semaglutide provided benefits beyond weight loss, including improvements in cardiometabolic health measures. The findings add to evidence that the GLP-1 receptor agonist affects multiple health outcomes. Semaglutide remains one of the most widely prescribed drugs for obesity and type 2 diabetes.
Researchers developed AAGP, a machine learning tool designed to predict potential anti-aging peptides. By analyzing over 4,000 physicochemical and compositional features, the model achieved high accuracy in distinguishing anti-aging peptides from other random or antimicrobial sequences. This computational approach aims to accelerate the discovery of peptide therapies for age-related decline.
Varró, Mándityné Huszka, Erdei, Mándoki and Mándity reported a continuous-flow solid-phase peptide synthesis platform that swaps toxic DMF/NMP for the greener solvent propylene carbonate. Published in Chemistry–Methods (May 2025), the method synthesized both α- and β-peptides at greater than 4-gram scale with good efficiency, pairing the throughput and automation advantages of continuous flow with a lower-toxicity, biodegradable solvent. The work tackles SPPS's chronic environmental weakness — huge volumes of hard-to-dispose polar aprotic solvents and a notoriously high Process Mass Intensity. As GLP-1-driven demand scales peptide manufacturing, greener high-throughput routes are becoming both a regulatory and a cost imperative.
On January 8, 2025, PolyPeptide Group announced a roughly €100 million investment to double solid-phase peptide synthesis (SPPS) capacity at its Malmö, Sweden plant, adding around 100 permanent jobs. The expansion is mainly tied to a long-standing GLP-1 customer agreement under one of the company's large commercial deals, with revenue contribution expected to begin in 2028. It reflects the global manufacturing crunch driven by GLP-1 agonist demand, which has outstripped existing peptide-API capacity and triggered comparable multi-hundred-million-euro build-outs at rivals such as Bachem and Lonza. Modular pre-built units were installed on-site during 2025 so existing production could keep running through the build-out.
Colston et al. clarified the molecular mechanism by which salcaprozate sodium (SNAC) — the absorption enhancer in oral semaglutide (Rybelsus) — lets peptides cross the gut epithelium. They show SNAC inserts into cell membranes and generates transient, fluid defects through which peptides like semaglutide slip. The work helps explain why oral semaglutide needs roughly 400 mg of SNAC for just 7–14 mg of peptide, and could inform next-generation oral peptide formulations beyond GLP-1s.
A denoising diffusion model from David Baker's Institute for Protein Design generates macrocyclic peptide binders against arbitrary protein targets. Tested on four targets, it produced nanomolar-affinity binders from fewer than 20 designs each, with crystal structures matching the computational models to within ~1.5 Å. Published in Nature Chemical Biology, the work signals that AI can now yield drug-like cyclic peptides on demand.
The peptides mentioned most often in our news coverage.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.